1. Home
  2. AUROW vs TGTX Comparison

AUROW vs TGTX Comparison

Compare AUROW & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AUROW

Aurora Innovation Inc. Warrant

HOLD

Current Price

$0.24

Market Cap

0.0

Sector

Technology

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$30.15

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUROW
TGTX
Founded
2017
1993
Country
United States
United States
Employees
1900
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
4.9B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
AUROW
TGTX
Price
$0.24
$30.15
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$49.80
AVG Volume (30 Days)
15.5K
1.9M
Earning Date
04-30-2025
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1746.67
EPS
N/A
2.77
Revenue
N/A
$2,785,000.00
Revenue This Year
N/A
$49.30
Revenue Next Year
N/A
$24.55
P/E Ratio
N/A
$10.95
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$25.37
52 Week High
$1.98
$46.48

Technical Indicators

Market Signals
Indicator
AUROW
TGTX
Relative Strength Index (RSI) 37.47 54.20
Support Level $0.16 $29.81
Resistance Level $0.30 $30.67
Average True Range (ATR) 0.03 1.40
MACD -0.01 0.18
Stochastic Oscillator 9.01 61.30

Price Performance

Historical Comparison
AUROW
TGTX

About AUROW Aurora Innovation Inc. Warrant

Aurora Innovation Inc delivers self-driving technology safely, quickly, and broadly. The Aurora Driver is a self-driving system designed to operate multiple vehicle types, from freight-hauling trucks to ride-hailing passenger vehicles. It underpins Aurora Horizon and Aurora Connect, its driver-as-a-service products for trucking and ride-hailing. The Company is developing the Aurora Driver, a scalable suite of self-driving hardware, software, and data services designed as a platform to adapt and interoperate among vehicle types and applications.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: